Phase 3,Single Arm,Open Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone Receptor Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
For more information about the trial above please contact the study team:
Principal Investigator, Gilbert Bader, at email@example.com.
Study Coordinator, Alexandria Green, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina